San Diego-based Trius Therapeutics, which is looking to IPO on the Nasdaq as TSRX, indicated in a filing today that it is looking to price its IPO at between $12.00 and $14.00 per share. The firm's IPO is being underwritten by Credit Suisse, Piper Jaffray, Canaccord Adams, and JMP Securities. Trius is focused on discovery, development, and commercialization of antibiotics. Trius is venture backed by Sofinnova venture Partners, InterWest, Versant Venture Capital.